Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701588 | 0.94 | MAPK1 (0.46) | HTR6MAPK1LMNACYP2C9 | |
| Hydrochloric Acid SCHEMBL274610 | 0.92 | MAPK1 (0.44) | HTR6MAPK1LMNACYP2C9 | |
| SCHEMBL12208387 | 0.88 | — | — | |
| SCHEMBL272039 | 0.88 | — | — | |
| SCHEMBL12029112 | 0.88 | — | — | |
| SCHEMBL16382274 | 0.88 | — | — | |
| Bromide SCHEMBL29867591 | 0.86 | LMNA (0.42) | HTR6MAPK1LMNACYP2C9 | |
| Hydrochloric Acid SCHEMBL9475384 | 0.86 | LMNA (0.42) | HTR6MAPK1LMNACYP2C9 | |
| Hydrochloric Acid SCHEMBL21378869 | 0.86 | LMNA (0.42) | HTR6MAPK1LMNACYP2C9 | |
| Hydrochloric Acid SCHEMBL841848 | 0.86 | LMNA (0.42) | HTR6MAPK1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994156-B2 | Carboxylic acid 4-phenylazo-phenyl ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-08-09 | — | — | US | disclosed |
| US-7910578-B2 | 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use | NEUROSEARCH A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-20100311699-A1 | NOVEL CARBOXYLIC ACID 4-PHENYLAZO-PHENYL ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-12-09 | — | — | US | disclosed |
| EP-2225212-A1 | NOVEL CARBOXYLIC ACID 4-PHENYLAZO-PHENYL ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009068595-A1 | NOVEL CARBOXYLIC ACID 4-PHENYLAZO-PHENYL ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-06-04 | — | — | WO | disclosed |
| US-20090099153-A1 | NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE | ANIONA APS (DK) | 2009-04-16 | — | — | US | disclosed |
| EP-2029607-A1 | NOVEL 8,10-DIAZA-BICYCLOÝ4.3.1¨DECANE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007135121-A1 | NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311699-A1 | NOVEL CARBOXYLIC ACID 4-PHENYLAZO-PHENYL ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | HTR6 86/4885MAPK1 3093/4885LMNA 4464/4885 |
| US-20090099153-A1 | NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE | CHRNA10, CHRNA7, CHRNA3 | HTR6 311/4885MAPK1 768/4885LMNA 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.